Phase 3 trials of the Sputnik V vaccine among citizens over 60 years of age have been successfully completed. According to Mikhail Murashko, head of the Ministry of Health, the trials showed a high level of safety and effectiveness of the drug. This year, Sistema-owned Binnopharm holding company has produced about 14% of Sputnik V produced in Russia by order of NRCEM named after Gamaleya, for ₽7.8 billion. The maximum cost of one set of doses of this vaccine is ₽1.94 thousand.